Key result
Enoxaparin used as early bridging anticoagulation after mechanical aortic valve replacement resulted in no thromboembolic events and a 5% rate of major bleeding.
Why the study?
Does enoxaparin bridging therapy safely prevent thrombo-embolic events without excessive bleeding in patients early after mechanical aortic valve replacement?
Cohort (n=40)
No
Does enoxaparin bridging therapy safely prevent thrombo-embolic events without excessive bleeding in patients early after mechanical aortic valve replacement?
Enoxaparin bridging therapy early after mechanical aortic valve replacement showed no thromboembolic events but was associated with a 5% rate of major bleeding, highlighting the need for larger randomized trials to confirm safety.
Answers are grounded in this paper and cite their sources.
Enoxaparin bridging warrants caution after mechanical AVR due to bleeding risk; leaves open safety confirmation in randomized trials.
Background: The use of low molecular weight heparin for early anticoagulation after mechanical aortic valve replacement is still a matter of debate even more that the early postoperative phase is associated with maximum of thrombo-embolic and bleeding risks. The objective of this study is to verify the efficacy and the safety of low molecular weight heparin for the early anticoagulation after mechanical aortic valve replacement. Methods and Results: It is a prospective study conducted over 6 months and interested 40 consecutive patients (32 male and 8 female) with a mean age 53.83 16.93 years (19 -75 years) who underwent a mechanical aortic valve replacement and received enoxaparin as bridging therapy between continuous unfractionated heparin and fully effective vitamin K antagonist therapy. There was no in-hospital death and no in-hospital thromboembolic events. We report 2 major bleeding events (5%). Conclusion: The use of low molecular weight heparin should be an alternative to explore for early anticoagulation after valve heart surgery and the results of our study must be verified by large randomized studies before drawing any hasty conclusions.
No takes yet. Share an insight, caveat, or question.
Moutakiallah et al. (2014) conducted a cohort in Mechanical Aortic Valve Replacement (n=40). Enoxaparin was evaluated on Rate of thromboembolic and major bleeding events during the early postoperative phase. Enoxaparin used as early bridging anticoagulation after mechanical aortic valve replacement resulted in no thromboembolic events and a 5% rate of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: